Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Solid Tumours
DRUG: ODM-212
Incidence and frequency of treatment emergent adverse events (TEAE), A TEAE is defined as any event arising or worsening after the start of treatment administration until 28 days after the last treatment intake., From first dose to 1 year after LSLV|Severity of TEAE, All AEs (except proteinuria which is to be graded according to urine albumin/creatinine ratio (UACR) category) will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0, From first dose to 1 year after LSLV
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours